Biogen Inc. $BIIB Shares Acquired by Truist Financial Corp

Posted by on May 14th, 2026

Truist Financial Corp lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 27.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,407 shares of the biotechnology company’s stock after purchasing an additional 2,450 shares during the quarter. Truist Financial Corp’s holdings in Biogen were worth $2,008,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Artemis Investment Management LLP acquired a new position in shares of Biogen during the 4th quarter worth $39,922,000. Composition Wealth LLC acquired a new position in shares of Biogen during the 4th quarter worth $223,000. One Wealth Advisors LLC acquired a new position in shares of Biogen during the 4th quarter worth $282,000. Fifth Third Bancorp grew its stake in shares of Biogen by 2.2% during the 4th quarter. Fifth Third Bancorp now owns 9,212 shares of the biotechnology company’s stock worth $1,621,000 after purchasing an additional 202 shares during the period. Finally, Danske Bank A S boosted its position in Biogen by 8.3% during the fourth quarter. Danske Bank A S now owns 48,415 shares of the biotechnology company’s stock worth $8,521,000 after purchasing an additional 3,705 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Stock Up 2.6%

Shares of NASDAQ:BIIB opened at $204.53 on Thursday. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 52-week low of $119.18 and a 52-week high of $205.97. The stock’s fifty day simple moving average is $185.01 and its 200-day simple moving average is $178.95. The company has a market capitalization of $30.20 billion, a P/E ratio of 21.95, a P/E/G ratio of 1.75 and a beta of 0.19.

Biogen (NASDAQ:BIIB – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the prior year, the business earned $3.02 earnings per share. The business’s revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities research analysts forecast that Biogen Inc. will post 14.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on BIIB. UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $185.00 to $225.00 in a research report on Wednesday, April 22nd. HC Wainwright increased their price objective on shares of Biogen from $228.00 to $237.00 and gave the company a “buy” rating in a research note on Thursday, April 2nd. Wedbush raised their target price on shares of Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a report on Thursday, April 30th. Piper Sandler upgraded shares of Biogen from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $177.00 to $214.00 in a research report on Tuesday, April 14th. Finally, Oppenheimer lifted their target price on shares of Biogen from $250.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 1st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $214.23.

Read Our Latest Report on BIIB

About Biogen

(Free Report)

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

Read More

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.